Samsung has entered into a partnership with decentralized science (DeSci) and healthcare artificial intelligence protocol Galeon to enhance the use of medical data through AI training. The collaboration focuses on integrating Samsung’s ultrasound equipment with Galeon’s electronic health record (EHR) platform, which is already being used in multiple interconnected hospitals.
The EHR platform, managed by Galeon, is currently operational across 18 hospitals, including several major institutions in France such as Rouen University Hospital, Caen University Hospital, Toulon Hospital, and Sud Francilien Hospital. Through this integration, Samsung and Galeon aim to boost the accessibility of medical data while maintaining a strong commitment to privacy.
According to Galeon’s leadership, the arrangement ensures that no patient data is stored directly on blockchain networks. Instead, only the AI algorithm functions onchain, with complete traceability of its operations. Additionally, all medical data undergoes anonymization before being utilized for training purposes, in compliance with privacy regulations.
This setup enables hospitals and healthcare providers to leverage the benefits of AI model training without losing control of their own patient information. Each institution continues to manage its own data while collectively contributing to the development of improved AI algorithms.
Practical Applications of Medical AI
Galeon’s team indicated that this decentralized approach is already yielding results in real-world medical processes. Developments include an AI system that automates billing for healthcare services, another tool that generates summaries of patient consultations, and an upcoming speech-to-text solution designed specifically for clinical settings. These advancements are being presented as evidence of how decentralized AI training can enhance efficiency in the medical sector.
DeSci’s Growing Role in Medicine
The partnership also highlights how healthcare has become one of the most dynamic areas within the decentralized science movement. Observers from organizations such as VitaDAO, a decentralized collective dedicated to longevity research, noted that high costs and lengthy timelines in conventional drug development are pushing innovators to explore DeSci models. Such approaches allow communities and independent researchers to address medical challenges without being tied solely to traditional pharmaceutical structures.
Earlier this year, another DeSci initiative, HydraDAO, reported that one of its projects led to spinally transected rats regaining the ability to walk within five days. Reports of such progress have attracted attention from investors, further boosting interest in decentralized medical research.
𝗚𝗮𝗹𝗲𝗼𝗻 𝗮𝗻𝗱 𝗦𝗮𝗺𝘀𝘂𝗻𝗴 𝗽𝗮𝗿𝘁𝗻𝗲𝗿.
A new alliance unleashing the power of medical innovation in Web3.A first step to address one of healthcare ’s biggest challenges: integrating data across tools, systems, environments.
The power of EHR software, fueled by… pic.twitter.com/RXtslIwoBY— Galeon (@GaleonCare) September 23, 2025
Investors Back DeSci Platforms
Investment activity in DeSci has been increasing, as seen in the case of Bio Protocol, a platform that recently secured $6.9 million in funding from notable backers such as Maelstrom Fund and Animoca Brands. This fundraising round followed a previous investment by Binance Labs, the venture capital arm of the major cryptocurrency exchange, in late 2024.
The competition for valuable health-related data remains intense. Several DeSci platforms are reportedly vying to acquire genetic data previously managed by DNA testing company 23andMe, which has faced financial difficulties. With data playing a central role in these initiatives, such developments are seen as crucial for fueling the next phase of decentralized medical innovation.
In essence, Samsung’s collaboration with Galeon reflects a broader trend where decentralized science and AI intersect to address pressing challenges in healthcare. By combining advanced medical imaging technology with privacy-focused AI training, the partnership demonstrates how innovation in DeSci is gradually transitioning from experimental projects to practical, hospital-level solutions.
